

ASX RELEASE

29th September 2023

AACR PANCREATIC CANCER CONFERENCE PRESENTATION

HIGHLIGHTS

- *Preclinical data from pancreatic cancer studies presented at premier international conference in Boston, USA.*
- *Data from these studies further support combination of narmafotinib (AMP945) with chemotherapy in pancreatic cancer.*
- *Plans are underway for a clinical trial of narmafotinib in combination with FOLFIRINOX.*

Melbourne, Australia: Amplia Therapeutics Limited (ASX: ATX), (“Amplia” or the “Company”) is pleased to announce that a poster, detailing a series of preclinical studies in pancreatic cancer models, was presented overnight at the **AACR SPECIAL CONFERENCE IN CANCER RESEARCH: PANCREATIC CANCER** meeting, being held in Boston, USA. The poster describes work conducted by our collaborators at the Garvan Institute of Medical Research, Sydney, and was presented by postdoctoral researcher Dr Kendelle Murphy.

A copy of the presentation is attached to this announcement.

Amplia’s CEO Dr Chris Burns commented: “We are delighted that this extensive body of research from the Garvan Institute on our best-in-class FAK inhibitor narmafotinib is being presented at such a prestigious conference. The Garvan team have done an outstanding job and this poster represents the first public disclosure of the breadth of that work demonstrating the impressive activity of the drug in these preclinical studies.”

The poster shows data demonstrating that in disease-bearing mice narmafotinib (AMP945) significantly reduces pancreatic cancer associated fibrosis through inhibition of FAK activity. Further, in a number of in vivo pancreatic cancer models, narmafotinib can be utilized to improve chemotherapy response.

Dr Burns continued: “This new preclinical data provides additional support for the activity of narmafotinib in combination with the two major chemotherapy regimens for pancreatic cancer. Plans are underway to start clinical trials using narmafotinib in combination with FOLFIRINOX in a similar design to the ACCENT trial.”

This ASX announcement was approved and authorised for release by the Board.

- End -

Investor Contact:

Dr Chris Burns
Chief Executive Officer
chris@ampliatx.com

Media Contact:

HACK Director, Haley Chartres
haley@hck.digital
+61 423 139 163

About Amplia Therapeutics Limited

Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer and Amplia has a particular development focus in fibrotic cancers such as pancreatic cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF). For more information visit www.ampliatx.com and follow Amplia on [Twitter](https://twitter.com/ampliatx) (@ampliatx), [Threads](https://www.threads.net/@ampliatx) (@ampliatx) and [LinkedIn](https://www.linkedin.com/company/amplia-therapeutics).